ArticleCureus2025
Posterior Reversible Encephalopathy Syndrome: The Eyes Reflecting Systemic Health.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Posterior reversible encephalopathy syndrome (PRES) is a condition marked by reversible subcortical brain swelling, often accompanied by acute neurological symptoms. It is commonly associated with renal failure, blood pressure fluctuations, cytotoxic drugs, autoimmune disorders, and preeclampsia or eclampsia. We report the case of a 34-year-old female who developed sudden blurring of vision in both eyes after an episode of accelerated hypertension. Neurological imaging revealed features of PRES, and fundoscopy showed hypertensive retinopathy in both eyes. She was managed aggressively in the ICU, and her best corrected visual acuity improved after one week, with gradual resolution of the hypertensive retinopathy. PRES typically follows a benign course, with visual deficits often resolving as the underlying systemic condition improves.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.